Haploidentical hematopoietic stem cell transplantation as promising therapy in the improved survival of pediatric patients with leukemias and myelodysplasias
作者机构：Instituto Multidisciplinar em SaúdeUniversidade Federal da BahiaVitória da Conquista 45029-094BahiaBrazil
出 版 物：《World Journal of Meta-Analysis》 (世界荟萃分析杂志)
年 卷 期：2023年第11卷第5期
页 面：181-195页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Haploidentical Stem cell transplantation Children Cancer Treatment outcome Prognosis
摘 要：BACKGROUND Haploidentical hematopoietic stem cell transplantation(Haplo-HSCT)is often performed in children with hematologic *** with the gap in the literature regarding the approach to experiences related to Haplo-HSCT with pediatric patients with leukemias and myelodysplasias aged up to 18 years,there was an interest in exploring the clinical outcomes of patients undergoing this *** To identify and summarize the scientific contributions available on Haplo-HSCT performed in the last 10 years in children and adolescents with myeloid and lymphoid leukemias and myelodysplasias,aged up to 18 *** This is a descriptive systematic *** extracted data including characteristics of participants,health condition,characteristics of the donation,conditioning regimen,recurrent clinical complications and clinical *** Virtual Health Library Brazil,PubMed,EMBASE,and SciELO platforms were used,finding a total of 1052 *** the eligibility criteria and complete reading of the texts,18 articles were included for *** The total sample of all study cohorts was 1825 patients,mostly male,the highest reported median age was 15.0 years and the lowest was 1.2 *** graftversus-host disease and chronic graft-versus-host disease were observed in almost all ***,graft rejection and delayed immune recovery were identified as major clinical ***-transplant minimal positive residual disease was identified in 288 *** are also among the main clinical complications,viral,bacterial and fungal infections being *** is observed that in the 5-year interval,the lowest rates of EFS and overall survival(OS)were 29.5%and 68.0%,***,the highest rates of EFS and OS,in the same interval,were 80.1%and 81.0%.CONCLUSION Haplo-HSCT represents a promising therapy,considering the potential number of possible donors and the conditioning and treatment platforms that can be *** res
维普期刊数据库